This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

How does siRNA work, and what makes it so different? To target a particular gene via siRNA, researchers actually target its messenger RNA, an intermediary in protein production made by transcribing ...

siRNA—which stands for short interfering ... But the existing treatments do not work well for everyone. Monoclonal treatments need to be re-developed as variants emerge and repurposed antiviral ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

While Roche ($RHHBY) and Sanofi ($SNY) are expanding their investments in RNAi, Merck ($MRK) is getting out. The pharma giant struck a deal to sell Sirna Therapeutics ...

Hansoh Pharmaceutical is making a multifront push into siRNA. Days after disclosing a ... up to $1.3 billion in milestones for the chance to work with Silence. In return for the outlay, Hansoh ...

The funds from this round will further advance our clinical programs and expand our pipeline, to deliver "transformative siRNA therapeutics for patients with chronic diseases" around the world." ...